ENFN vs. BASE, EVBG, WKME, SEMR, AVID, SCWX, VTEX, DDD, DCBO, and CCSI
Should you be buying Enfusion stock or one of its competitors? The main competitors of Enfusion include Couchbase (BASE), Everbridge (EVBG), WalkMe (WKME), Semrush (SEMR), Avid Technology (AVID), SecureWorks (SCWX), VTEX (VTEX), 3D Systems (DDD), Docebo (DCBO), and Consensus Cloud Solutions (CCSI). These companies are all part of the "prepackaged software" industry.
Enfusion vs.
Enfusion (NYSE:ENFN) and Couchbase (NASDAQ:BASE) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.
In the previous week, Couchbase had 7 more articles in the media than Enfusion. MarketBeat recorded 8 mentions for Couchbase and 1 mentions for Enfusion. Enfusion's average media sentiment score of 0.43 beat Couchbase's score of 0.24 indicating that Enfusion is being referred to more favorably in the media.
49.4% of Enfusion shares are held by institutional investors. Comparatively, 59.2% of Couchbase shares are held by institutional investors. 40.1% of Enfusion shares are held by insiders. Comparatively, 24.6% of Couchbase shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Enfusion has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Couchbase has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Enfusion has a net margin of 1.81% compared to Couchbase's net margin of -44.24%. Enfusion's return on equity of 2.81% beat Couchbase's return on equity.
Couchbase received 22 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 39.73% of users gave Couchbase an outperform vote while only 17.50% of users gave Enfusion an outperform vote.
Enfusion currently has a consensus target price of $11.08, suggesting a potential upside of 37.00%. Couchbase has a consensus target price of $19.40, suggesting a potential downside of 7.75%. Given Enfusion's higher possible upside, research analysts clearly believe Enfusion is more favorable than Couchbase.
Enfusion has higher earnings, but lower revenue than Couchbase. Couchbase is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Summary
Enfusion beats Couchbase on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENFN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Enfusion Competitors List
Related Companies and Tools